SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) June 2, 2011
NOVADEL PHARMA INC.
(Exact Name of Registrant as Specified in Its Charter)
1200 Route 22 East, Suite 2000
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Item 8.01. Other Events.
On June 2, 2011, NovaDel Pharma Inc., a Delaware corporation (the “Company”) announced that the Company opened an original Investigational New Drug application with the United States Food and Drug Administration for its lead development program Duromist™, its sildenafil oral spray product for the treatment of erectile dysfunction.
The full text of the press release is set forth in Exhibit 99.1 hereto and incorporated herein.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.